115-71-9
CAS 115-71-9
115-71-9 (CAS 115-71-9) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 16.6 ug.mL-1 | 8 | - |
| - | GI50 | 4385.714285714285 nM | 7 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 115-71-9 used for in pharmaceutical contexts?
115-71-9 (CAS 115-71-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 115-71-9?
No adverse-event association or SIDER side-effect rows are rendered for 115-71-9 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 115-71-9 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Alpha-Santalol with EU status "permitted".
What clinical phase is 115-71-9 in?
No phase 1-4 clinical development badge is rendered for 115-71-9 because the matched compound identifier rows do not contain a max-phase value.